A poor vitamin D status, i.e. low serum levels of 25-hydroxyvitamin D [25(OH)D], is common in the general population. This finding is of concern not only because of the classic vitamin D effects on musculoskeletal outcomes, but also because expression of the vitamin D receptor (VDR) and vitamin D metabolizing enzymes in the heart and blood vessels suggests a role of vitamin D in the cardiovascular system. VDR-knockout mice suffer from cardiovascular disease (CVD), and various experimental studies suggest cardiovascular protection by vitamin D, including antiatherosclerotic, anti-inflammatory and direct cardio-protective actions, beneficial effects on classic cardiovascular risk factors as well as suppression of parathyroid hormone (PTH) levels. In epidemiological studies, low levels of 25(OH)D are associated with increased risk of CVD and mortality. Data from randomized controlled trials (RCTs) are sparse and have partially, but not consistently, shown some beneficial effects of vitamin D supplementation on cardiovascular risk factors (e.g. arterial hypertension). We have insufficient data on vitamin D effects on cardiovascular events, but meta-analyses of RCTs indicate that vitamin D may modestly reduce all-cause mortality. Despite accumulating data suggesting that a sufficient vitamin D status may protect against CVD, we still must wait for results of large-scale RCTs before raising general recommendations for vitamin D in the prevention and treatment of CVD. In current clinical practice, the overall risks and costs of vitamin D supplementation should be weighed against the potential adverse consequences of untreated vitamin D deficiency.
Introduction
Vitamin D is classically known for its crucial role in calcium and bone metabolism.
1,2 Recent advances in research provoked enormous public health interest in vitamin D: (i) the vitamin D receptor (VDR) was identified in almost all human cells, 2 (ii) vitamin D deficiency was shown to be highly prevalent among general populations 3 and (iii) vitamin D deficiency has been associated with various chronic diseases including cardiovascular diseases (CVDs), which are the leading causes of death. 1,2, 4 In this review, we summarize and discuss current knowledge on the association of vitamin D with CVD and mortality. We start with an overview of vitamin D metabolism, vitamin D's history in science and the current prevalence of vitamin D deficiency. Then, we summarize mechanistic and clinical data on the role of vitamin D for the cardiovascular system and for CVD risk factors. Finally, we present epidemiological and interventional data of vitamin D administration, CVD and mortality and offer some guidance for treating vitamin D deficiency.
to previtamin D, which spontaneously isomerises to vitamin D. 6 This vitamin D production by sunlight exposure is particularly efficient in individuals with low levels of skin melanin. Therefore, an intriguing hypothesis suggests that in human evolution, those individuals migrating to northern regions developed a fair skin to efficiently synthesize vitamin D under conditions of less UV-B exposure, whereas those individuals residing in sunny regions have a high melanin content of the skin, which protects against sunlightinduced damage. 7, 8 Diet makes a relatively small contribution to vitamin D status. 1, 5 Vitamin D can be obtained from natural foods (e.g. oily fish, eggs or UV-irradiated and sun-dried mushrooms), vitamin D-fortified food (e.g. vitamin D-fortified milk and orange juice in the United States) or vitamin D supplements. 1 Two major forms of vitamin D exist: vitamin D3 (cholecalciferol), the main vitamin D form derived mainly from synthesis in the skin and from animal sources and vitamin D2 (ergocalciferol), the plant-and yeast-derived form. Unless otherwise stated, we do not differentiate between these two isoforms in this review and usually refer to vitamin D (meaning both vitamin D2 and D3) in general. Vitamin D as a precursor compound exerts no significant biological activity. Two hydroxylation steps are required to produce the most active vitamin D metabolite, 1,25-dihydroxyvitamin D [1,25(OH)2D]. 6 First, vitamin D from any source is hydroxylated to 25(OH)D. This is generally a substrate-dependent process that occurs mainly in the liver. Then, the enzyme 1a-hydroxylase converts 25(OH)D to 1,25(OH)2D. The kidney is the major site for production of circulating 1,25(OH)2D. 4, 20 This optimal range, which lies exactly in the middle of the IOM vitamin D sufficiency range, is however based only on observational data including achieved 25(OH)D concentrations from meta-analyses of randomized controlled trials (RCTs) because no published interventional studies exist on, for example, CVD or mortality outcomes with specific target concentrations of 25(OH)D. 4 Therefore, any vitamin D status classification, including the one we propose (see Fig. 1 ), is debatable unless sufficient data from RCTs are available to support that targeting certain 25(OH)D ranges reduces hard end-points such as CVD or mortality. 25(OH)D levels of 250 nm can be considered as safe and are used by several reference laboratories as the safe upper limit of normal. This safe upper limit of normal is based mainly on the evidence level of an expert opinion and was chosen because 25(OH)D concentrations of 250 nm can be achieved but are rarely exceeded by healthy subjects who have spent prolonged periods in a sunny environment. 4, 21 However, only limited clinical data are available on the long-term prognosis of individuals with 25(OH)D levels >125-150 nm. 4 Vitamin D toxicity begins at 25(OH)D levels >375-500 nm (see Fig. 1 ). 25 Wang et al.
25
found three genetic loci that were significantly related to 25(OH)D levels. One gene is involved in metabolism of the vitamin D precursor 7-dehydrocholesterol, another one encodes an enzyme with 25-hydroxylase activity and the third one is the DBP.
One should also consider different characteristics of 25(OH)D assays when determining vitamin D status. 26 Whereas data on cutoff levels for vitamin D status are generally based on the DiaSorin radioimmunoassay, the increasing request for 25(OH)D measurements has prompted the development of various automated immunoassays. 26 
Vitamin D and cardiovascular risk factors
In the following, we summarize clinical and mechanistic evidence on the effect of vitamin D status on cardiovascular risk factors (see Fig. 2 ). PTH levels are inversely correlated with 25(OH)D concentrations, and epidemiological studies demonstrated that elevated and high-normal PTH levels are associated with an increased risk of cardiovascular events and mortality. 27 Mechanistically, PTH increases blood pressure and exerts various effects on the heart including myocardial hypertrophy and pro-arrhythmic actions. 28 PTH suppression by vitamin D supplementation might therefore reduce cardiovascular risk. Low 25(OH)D levels are an independent risk factor for prevalent and incident hypertension. 29 Moreover, meta-analyses of RCTs documented that vitamin D supplementation lowers systolic blood pressure by 2-6 mmHg. [30] [31] [32] This latter effect was statistically significant in two of three meta-analyses. [30] [31] [32] Proposed antihypertensive effects of vitamin D include PTH suppression, reno-and vasculo-protective properties, and anti-inflammatory and antidiabetic actions. In addition, 1,25(OH)2D has been shown to suppress renin transcription. 2,33 Molecular pathways for this effect have already been clarified, and this finding is in line with observations of VDR-and 1a-hydroxylase-knockout mice, which display increased activity of the renin-angiotensin-aldosterone system (RAAS). 
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Patients with CKD are particularly prone to low 25(OH)D levels. 34 This outcome can be attributed to morbidity-related limitations in sunlight exposure, impaired vitamin D synthesis in the skin, malnutrition and disturbances in vitamin D metabolism, such as loss of protein-bound vitamin D metabolites via the urine in proteinuric patients. 34 Interestingly, a poor vitamin D status is a risk factor for decline in renal function. 34 This may be explained by several reno-protective effects of vitamin D such as antiproteinuric (e.g. vitamin D might increase megalin-mediated tubular protein reabsoprtion) and antihypertensive properties, suppression of the RAAS, and anti-inflammatory and anti-autoimmunological actions.
5,34
A poor vitamin D status is partially, but not consistently, associated with a higher prevalence and incidence of type 2 diabetes mellitus. 35 Vitamin D metabolites stimulate insulin secretion and improve insulin sensitivity, for example, by upregulating the insulin receptor. 35 Some, but not all, interventional studies have shown that vitamin D supplementation improves glucose metabolism for example, by reducing insulin resistance. 35 Vitamin D may also be important for preventing type 1 diabetes mellitus. Low vitamin D intake during childhood and low solar UV-B radiation are associated with an increased risk of developing type 1 diabetes mellitus. 35, 36 In addition, variants of genes involved in vitamin D metabolism and related to 25(OH)D levels are associated with risk of type 1 diabetes. 37 Vitamin D affects autoimmunological processes by increasing regulatory T cells (Tregs), which protect against autoimmunity. 38 Whether vitamin D supplementation is definitely useful to prevent or treat type 1 and type 2 diabetes mellitus remains to be proven in RCTs. Some RCTs have already documented anti-infectious and antiinflammatory actions of vitamin D such as reduction in the inflammation marker tumour necrosis factor-a (TNF-a) and increases in the anti-inflammatory cytokine interleukin-10 (IL-10).
2,39-41
Vitamin D may also affect other cardiovascular risk factors such as blood lipids or coagulation parameters but currently available data are insufficient to draw final conclusions.
42,43
Vitamin D effects on heart and blood vessels
Evidence is accumulating that vitamin D may also exert various direct effects on the cardiovascular system (see Fig. 3 ). Heart and blood vessels are target tissues for vitamin D and express both VDR and 1a-hydroxylase.
2, [44] [45] [46] [47] In the following, we summarize experimental and observational clinical studies on the role of vitamin D for the heart and blood vessels. Vitamin D receptor-knockout and 1a-hydroxylase-knockout mice develop heart failure despite normalized calcium levels.
2, 45, 48, 49 Increased activation of the RAAS seems to be the mediating pathway because RAAS blockade with, for example, the angiotensin-converting enzyme (ACE)-inhibitor captopril reverses cardiac abnormalities in these mouse models. 45, 53 In this context, a study of 171 healthy British Bangladeshi adults showed that matrix metalloproteinase-9 is elevated in vitamin D deficient individuals but is significantly decreased after vitamin D supplementation. 53 Several clinical studies confirmed that heart failure patients have a poor vitamin D status, but whether vitamin D deficiency is only the consequence of heart failure or possibly contribute to myocardial diseases is unclear. 45 Interventional trials produced inconsistent results on the effect of vitamin D on parameters of myocardial structure and function warranting further large-scale RCTs. 40, 45 Vitamin D may also protect against atherosclerosis, vascular calcification and endothelial dysfunction. 44 Antiatherosclerotic vitamin D effects may include (i) inhibition of macrophage cholesterol uptake and foam cell formation, (ii) downregulation of vascular smooth muscle cell proliferation and migration, and (iii) suppression of inflammation-triggered endothelial activation and expression of endothelial adhesion molecules. 44, [54] [55] [56] Vitamin D effects may also protect against endothelial dysfunction, for example, by antioxidative actions and by inhibiting lipid peroxidation. 44, 57 Finally, vitamin D may reduce vascular calcification, for example, by inhibiting bone morphogenic proteins, but data on this topic are somewhat controversial. 44, 58 This could be attributed to the fact that both a poor vitamin D status as well as vitamin D intoxication may contribute to vascular calcification, although it should be noted that the largest study on vitamin D plus calcium supplementation found no effect on coronary artery calcification. 54, 59 Observational 
Vitamin D and CVDs

Observational data
Accumulating evidence suggests that CVD is associated with vitamin D deficiency. Various epidemiological studies have reported reduced 25(OH)D concentrations in patients with previous and prevalent cardiovascular or cerebrovascular diseases. 44, 45, [63] [64] [65] [66] Several prospective studies have addressed this issue, including the Intermountain Heart Collaborative Study, which included >40 000 individuals from a general healthcare population. 65 In this study, individuals with low serum concentrations of 25(OH)D were at significantly increased risk for future CVD, in particular for heart failure and cerebrovascular events. 65 Consistent with this finding, population-based studies have partially, but not consistently, documented that poor vitamin D status is associated with an increased risk of cardiovascular events and cardiovascular mortality (see Table 1 ). 66 
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However, one must interpret all these above-mentioned observational studies in the light that sun exposure habits, which may be an important confounder for the association between 25(OH)D and CVD, significantly determine vitamin D status. Furthermore, nutritional intake of vitamin D is usually related to other micronutrients (e.g. vitamins D and A in cod liver oil), which interferes with the ability to evaluate how vitamin D status affects CVD. Apart from this, vitamin D-independent effects of sunlight exposure might partially drive the association of vitamin D status with CVD. Cardiovascular risk factors and CVD may also have a reciprocal effect on vitamin D status (e.g. vitamin D may affect myocardial function, but impaired myocardial function may cause vitamin D deficiency owing to morbidity-associated limitation of sunlight exposure).
Single-nucleotide polymorphisms (SNPs) of the VDR and of key enzymes for vitamin D metabolism have also been associated with left ventricular hypertrophy, heart failure and coronary artery calcification. [83] [84] [85] Even though some questions on the functionality of these SNPs remain unresolved, these latter results may further support a possible causal relationship between vitamin D metabolism and CVD.
83-85
Data from interventional studies
Results of RCTs designed primarily to assess effects of vitamin D supplementation on CVD are still missing. Data on vitamin D and CVD are derived mainly from studies designed to evaluate vitamin D¢s effect on musculoskeletal outcomes. 86 Most of those studies evaluated the impact of combined calcium plus vitamin D supplementation. 86 This approach limits the ability to differentiate the effects of vitamin D from those of calcium. This factor may be important because calcium per se might even be harmful in terms of cardiovascular outcomes. 86, 87 A systematic review identified two
RCTs with exclusive vitamin D supplementation that reported on CVD events as a secondary outcome. 86 These studies, with vitamin D doses of approximately 1000 IU per day, found a moderate, but statistically nonsignificant, reduction in CVD risk [pooled relative risk, 0AE90 (95% CI, 0AE77-1AE05)] in the vitamin D group. 86 Further large studies have been initiated to definitively prove whether vitamin D supplementation reduces CVD in the general population, but these studies will still take several years (e.g. the VITAL; see http://www.vitalstudy.org).
Vitamin D and total mortality
Beyond CVD, vitamin D deficiency is associated with increased risk of total mortality. Most, but not all, studies on this topic documented increased mortality in patients with low 25(OH)D concentrations. 68, [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] A meta-analysis among 6853 patients with CKD
showed that mortality risk decreases by 14% [relative risk 0AE86 (95% CI 0AE82-0AE91)] per 25 nm increase in 25(OH)D levels. 88 This finding is in line with the results of a meta-analysis of RCTs including mainly studies on frail, elderly patients. 89 In this report of 93 Therefore, we should be cautious with high-dose vitamin D supplementation also when considering that some study results suggest a J-shaped association between 25(OH)D and mortality. 70 Individual variations in response to vitamin D supplementation should be considered, and in particular, obese individuals require higher doses as a result of vitamin D depletion in the adipose tissue. 4 In patients with vitamin D insufficiency or deficiency, it has been shown that the lower the baseline 25(OH)D levels, the greater is the increase in 25(OH)D after vitamin D supplementation. 94 Retesting of 25(OH)D concentrations may therefore be reasonable, also in an effort to improve compliance, but this should be carried out only 3 months after initiation of vitamin D supplementation which is the time necessary to reach a plateau. 4 No adverse effects have been observed with daily vitamin D intakes of up to 10 000 IU. 95 Potential side effects of vitamin D (i.e. vitamin D intoxication) are seen at 25(OH)D serum levels >375-500 nm and are related to symptoms of hypercalcaemia with the risk of calcifications (e.g. of the vessels or the kidney) and hypercalciuria with dehydration and renal failure. 95 No convincing evidence exists that vitamin D supplementation alone increases the risk of kidney stones, but the combined supplementation of calcium plus vitamin D may be associated with significantly increased incidence of kidney stones. 95 Increased sunlight exposure of the skin can also significantly increase 25(OH)D serum concentrations. Sunlight-induced vitamin D synthesis in the skin can be equivalent to a daily vitamin D supplementation of up to 10 000-20 000 IU. 75 -100 nm are associated with the best health outcomes, and we therefore believe that aiming for this 'optimal range' of vitamin D status is reasonable. However, we should be aware that these data on the optimal vitamin D status are based on relatively low evidence levels, are controversially discussed and need to be further evaluated in large-scale RCT.
